Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 3/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366376 | 0.78 | SCN4A (0.54) | SCN4AMCL1PARP10XDHCA1 | |
| SCHEMBL3367196 | 0.78 | SCN4A (0.54) | SCN4AMCL1PARP10XDHCA1 | |
| SCHEMBL27560770 | 0.76 | SCN4A (0.52) | SCN4AMCL1PARP10XDHCA1 | |
| SCHEMBL3367401 | 0.76 | SCN4A (0.52) | SCN4AMCL1PARP10XDHCA1 | |
| SCHEMBL1384820 | 0.70 | SCN4A (1.00) | SCN4AMCL1PARP10XDHCA1 | |
| SCHEMBL14190748 | 0.67 | LMNA (0.53) | SCN4AMCL1PARP10CHEK2BTK | |
| SCHEMBL3370342 | 0.67 | KMT2A (0.45) | SCN4AMCL1RAB9A | |
| SCHEMBL1758360 | 0.64 | PARP10 (0.57) | SCN4AMCL1PARP10CHEK2SCN9A | |
| SCHEMBL3990021 | 0.64 | SMN1; SMN2 (0.53) | SCN4AMCL1PARP10XDHNPC1 | |
| Diphenylether SCHEMBL10618785 | 0.63 | PARP10 (0.71) | PARP10CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| US-6737418-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | EURO-CELTIQUE S.A. (LU) | 2004-05-18 | — | — | US | disclosed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | SCN4A 598/4885MCL1 4182/4885PARP10 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.